GATC Biotech

The Epigenetics For Female Personalised Cancer Care (EpiFemCare) project recently published its findings in two papers in the journal Genome Medicine.

The deal will close in July and will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing. 

GATC will provide next-generation sequencing services for Constance research projects, and they will work together to further develop sequencing methods.

GATC Biotech said it selected Bluebee's platform for its service because of its increased automation and flexibility.

The company, based in Constance, Germany, is launching three liquid biopsy assays as a research service this week that differ in target size and sensitivity.

GATC Biotech will sell and market Molecular Health's TreatmentMap next-generation sequencing-based tumor profiling platform around the world.

The firm's divisions will include Sequencing Solutions, Customized Solutions, and Diagnostics Solutions.

NEW YORK (GenomeWeb) – A new cancer personalized treatment service that SAP is offering to employees living with the disease provides an opportunity for the company to put its newly minted SAP Genomic Analyzer solution — a sequence alignment and analysis software that runs on the SAP Hana infrast

GATC Biotech has launched three different transcriptome sequencing services. InView Transcriptome Explore provides random primed cDNA libraries for Illumina sequencing using 50 bp single reads and guarantees at least 30 million single reads.

NEW YORK (GenomeWeb News) – MolecularHealth today announced an agreement under which GATC Biotech will provide its laboratory information management system in MolecularHealth's new clinical laboratory.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.